SCPH Valuation

scPharmaceuticals Inc

Add to Watchlist

Advanced Chart

5.370

-0.01(-0.186%)1D

Overview
Forecast
Valuation
Earnings

SCPH Relative Valuation

SCPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SCPH is overvalued; if below, it's undervalued.

Historical Valuation

scPharmaceuticals Inc (SCPH) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.06 is considered Overvalued compared with the five-year average of -4.31. The fair price of scPharmaceuticals Inc (SCPH) is between 3.10 to 5.19 according to relative valuation methord. Compared to the current price of 5.37 USD , scPharmaceuticals Inc is Overvalued By 3.42%.

Relative Value

Fair Zone

3.10-5.19

Current Price：5.37

3.42%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-52.77

P/B

Median3y

3.84

Median5y

3.26

-25.85

FCF Yield

Median3y

-27.85

Median5y

-23.78

Competitors Valuation Multiple

The average P/S ratio for SCPH's competitors is 1.05, providing a benchmark for relative valuation. scPharmaceuticals Inc Corp (SCPH) exhibits a P/S ratio of 3.06, which is 191.49% above the industry average. Given its robust revenue growth of 92.59%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SCPH.O

scPharmaceuticals Inc

3.06

Average P/S: 1.05

92.59%